Spectrum CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France

Human Mutation

Volumn 16, Issue 2, 2000, Pages 143-156

  Claustres, Mireille ^a   Guittard, Caroline ^a   Bozon, Dominique ^b   Chevalier, Françoise ^b   Verlingue, Claudine ^c   Ferec, Claude ^c   Girodon, Emanuelle ^d   Cazeneuve, Cécile ^d   Bienvenu, Thierry ^e   Lalau, Guy ^f   Dumur, Viviane ^f   Feldmann, Delphine ^g   Bieth, Eric ^h   Blayau, Martine ⁱ   Clavel, Christine ^j   Creveaux, Isabelle ^k   Malinge, Marie Claire ^l   Monnier, Nicole ^m   Malzac, Perrine ⁿ   Mittre, Hervé ^o   Chomel, Jean Claude ^p   Bonnefont, Jean Paul ^q   Iron, Albert ^r   Chery, Michèle ^s   Georges, Marie Des ^a   more..

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b HÔPITAL DEBROUSSE   (France)

^c Centre de Biogénétique   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e université Paris Cité   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g ARMAND TROUSSEAU HOSPITAL   (France)

^h CHU PURPAN   (France)

ⁱ PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^j HÔPITAL MAISON BLANCHE   (France)

^k ONERA   (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

^m CHU La Tronche and University   (France)

ⁿ TIMONE HOSPITAL   (France)

^o CHU Clemenceau   (France)

^p POITIERS UNIVERSITY HOSPITAL   (France)

^q HÔPITAL NECKER ENFANTS MALADES   (France)

^r HÔPITAL PELLEGRIN   (France)

^s CHU NANCY BRABOIS   (France)

more..

Author keywords

ABCC7; CBAVD; CF; CFTR; Congenital absence of the vas deferens; Cystic fibrosis; France

Indexed keywords

DNA; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CONGENITAL MALFORMATION; CYSTIC FIBROSIS; FRANCE; GENE FREQUENCY; GENE MUTATION; GENETIC COUNSELING; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT MALFORMATION; PRIORITY JOURNAL; VAS DEFERENS;

EID: 0033860259     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-1004(200008)16:2<143::AID-HUMU7>3.0.CO;2-J     Document Type: Article

References (54)

1. Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher Ta, White MB, Milunsky A. 1992. Congenital bilateral absence of the vas deferens. A primary genital form of cystic fibrosis. J Am Med Assoc 267:1794-1797.
2. Antonarakis SE and the Nomenclature Working Group. 1998. Recommendations for a nomenclature system for human gene mutations, http://www.interscience.wiley.com/jpages/1059-7794/nomenclature.html. Hum Mutat 11:1-3.
3. Augarten A, Yahav Y, Kerem BS, Halle D, Laufer J, Szeinberg A, Dor J, Mashiach S, Bazit E, Madgar I. 1994. Congenital bilateral absence of vas deferens in the absence of cystic fibrosis. Lancet 344:1473-1474.
4. Bombieri C, Giorgi S, Carles S, de Cid R, Belpinati F, Tandoi C, Pallares-Ruiz N, Lazaro C, Ciminelli BM, Romey MC, Casals T, Pompei F, Gandini G, Claustres M, Estivill X, Pignatti PF, Modiano G. 2000. A new approach for identifying non-pathogenic mutations. An analysis of the cystic fibrosis transmembrane regulator gene in normal individuals. Hum Genet 106:172-178.
5. Bonizzato A, Bisceglia L, Marigo C, Nicolis E, Bombieri C, Castellani C, Borgo G, Zelante L, Mastella G, Cabrini G, Gasparini P, Pignatti PF. 1995. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from North-Eastern Italy: identification of 90% of the mutations. Hum Genet 95:397-402.
6. Casals T, Ramos M, Gimenez J, Larriba S, Nunes V, Estivill X. 1997. High heterogeneity for cystic fibrosis in Spanish families: 75 mutations account for 90% of chromosomes. Hum Genet 101:365-370.
7. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silbert S, Romey MC, Ruiz-Romero J, Verlingue C, Claustres M, Nunes V, Ferec C, Estivill X. 1995. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 332:1475-1480.
8. Chu CS, Trapnell B, Curristin SM, Cutting GR, Crystal RG. 1993. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 3:151-156.
9. Claustres M, Laussel M, Desgeorges M, Giansily M, Culard JF, Razakatsara G, Demaille J. 1993. Analysis of the 27 exons and flanking regions of the cystic fibrosis gene: 40 different mutations account for 91.2% of the mutant alleles in Southern France. Hum Mol Genet 2:1209-1213.
10. Costes B, Girodon E, Ghanem N, Flori E, Jardin A, Soufir JC, Goossens M. 1995. Frequent occurrence of the CFTR intron 8 (TG)n 5T allele in men with congenital bilateral absence of the vas deferens. Eur J Hum Genet 3:285-293.
11. Cotton RGH, Scriver CR. 1998. Proof of disease causing mutation. Hum Mutat 12:1-3.
12. Cuppens H, Marynen P, De Boeck C, Cassiman JJ. 1993. Detection of 98.5% of the mutations in 200 Belgian cystic fibrosis alleles by reverse dot-blot and sequencing of the complete coding region and exon/intron junctions of the CFTR gene. Genomics 18:693-697.
13. Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ. 1998. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101:487-496.
14. Cutting GR. 1997. Cystic fibrosis. In: Principles and practice of medical genetics 131. p 2685-2717.
15. Cystic Fibrosis Genetic Analysis Consortium. 1994. Population variation of common cystic fibrosis mutations. Hum Mutat 4:167-177.
16. Cystic Fibrosis Genetic Analysis Consortium. 1999. CFGAC: http://genet.sickids.on.ca.
17. De Braekeleer M, Ferec C. 1996. Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. Mol Hum Reprod 2:669-677.
18. De Meeus A, Guittard C, Desgeorges M, Carles S, Demaille J, Claustres M. 1998. Linkage disequilibrium between the M470V variant and the IVS8 polyT alleles of the CFTR gene in CBAVD. J Med Genet 35:594-596.
19. Dequeker E, Cassiman JJ. 1998. Evaluation of CFTR gene mutation testing methods in 136 diagnostic laboratories: report of a large European external quality assessment. Eur J Hum Genet 6:165-175.
20. Des Georges M, Guittard C, Bozon D, Chevalier F, Verlingue C, Ferec C, Girodon E, Cazeneuve C, Bienvenu T, Lalau G, Dumur V, Feldmann D, Bieth E, Blayau M, Clavel C, Creveaux I, Malinge MC, Monnier N, Malzac P, Mittre H, Bonnefont JP, Iron A, Chomel JC, Chery M, Claustres M. 1998. Les bases moléculaires de la mucoviscidose en France: plus de 300 mutations et 506 génotypes différents sont en cause. Médecine-Sciences 14:1413-1421.
21. Dork T, Dworniczak B, Aulehla-Scholz C, Wieczorek D, Böhm I, Mayerova A, Seydewitz HH, Nieschlag E, Meschede D, Horst J, Pander HJ, Sperling H, Ratjen F, Passarge E, Schmidtke J, Stuhrmann M. 1997. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 100:365-377.
22. Dumur V, Gervais R, Rigot JM, Lafitte JJ, Manouvrier S, Biserte J, Mazeman E, Roussel P. 1990. Abnormal distribution of CF δF508 allele in azoospermic men with congenital aplasia of epididymis and vas deferens. Lancet 336:512.
23. Dumur V, Gervais R, Rigot JM, Delomel-Vinner E, Decaestecker B, Lafitte JJ, Roussel P. 1996. Congenital bilateral absence of the vas deferens (CBAVD) and cystic fibrosis transmembrane regulator (CFTR): correlation between genotype and phenotype. Hum Genet 97:7-10.
24. Estivill X. 1996. Complexity in a monogenic disease. Nature Genet 12:348-350.
25. Estivill X, Bancells C, Ramos C. 1997. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. Hum Mutat 10:135-154.
26. Holsclaw DS, Perlmutter AD, Jockin H, Scwachman H. 1971. Genital abnormalities in male patients with cystic fibrosis. J Urol 106:568-574.
27. Kerem B, Kerem E. 1996. The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet 4:65-73.
28. Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M, Yahav Y, Goshen R, Bentur L, Rivlin J, Aviram M, Genem A, Chiba-Falek O, Kraemer MR, Simon A, Branski D, Kerem BS. 1997. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 155:1914-1920.
29. Ko YH, Pedersen PL. 1997. Frontiers in Research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease. J Bioenerg Biomembr 29:417-427.
30. Lissens W, Mercier B, Tournaye H, Bonduelle M, Ferec C, Seneca S, Devroey P, Silber S, Van Steirteghem A, Liebaers I. 1996. Cystic fibrosis and infertility caused by congenital absence of the vas deferens and related clinical entities. Hum Reprod 11, 34:55-80.
31. Mak V, Jarvi KA, Zielenski J, Durie P, Tsui LC. 1997. Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens. Hum Mol Genet 6:2099-2107.
32. Mak V, Zielenski J, Tsui LC, Durie P, Zini A, Martin S, Longley TB, Jarvi KA. 1999. Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia. J Am Med Assoc 281:2217-2224.
33. Meschede D, Dworniczak B, Nieschlag E, Horst J. 1998. Genetic diseases of the seminal ducts. Biomed & Pharmacother 52:197-203.
34. Mickle JE, Cutting GR. 1998. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clinics in Chest Medicine 19:443-458.
35. Oates RD, Amos JA. 1994. The genetic basis of congenital bilateral absence of the vas deferens and cystic fibrosis. J Androl 15:1-8.
36. Okada H, Yoshimura K, Fujioka H, Tatsumi N, Gotoh A, Fujisawa M, Gohji K, Arakawa S, Kato H, Kobayashi SI, Isojima S, Koshida M, Kaminodo S. 1999. Assisted reproduction technology for patients with congenital bilateral absence of vas deferens. J Urol 161:1157-1162.
37. Rave-Harel N, Kerem E, Nissim-Rafinia M, Madjar I, Goshen R, Augarten A, Rahat A, Hurwitz A, Darvasi A, Kerem BS. 1997. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet 60:87-94.
38. Riordan JR. 1999. Cystic fibrosis as disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein. Am J Hum Genet 64:1499-1504.
39. Rosenstein BJ, Cutting G. 1998. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 132:589-595.
40. Rozmahel R, Heng HHQ, Duncan AMV, Shi XM, Rommens JM, Tsui LC. 1997. Amplification of CFTR exon 9 sequences to multiple locations in the human genome. Genomics 45:554-561.
41. Schlegel PN, Shin D, Goldstein M. 1996. Urogenital anomalies in men with congenital absence of the vas deferens. J Urol 155:1644-1648.
42. Schwarz MJ, Malone GM, Haworth A, Cheadle JP, Meredith A, Gardner A, Hilary Sawyer I, Connarty M, Dennis N, Seller A, Harris A, Taylor R, Dear S, Middleton-Price H, McMahon C, Mayall Ed, McMahon R, Barton DE, Giles M, Lindley V, Plaha DS, Price S, Sharif A, Cross GS, Dalton A, Taylor G, Wallace A, Tassabehji M, Whittaker JL, Butler R, Curtis A, Pinkett R, Gilfillan AJ, Brock DJH, Higgins GS, Lanyon G, Miedzybrodzka Z, Davidson M, Graham CA, Hill A. 1995. Cystic fibrosis mutation analysis: report from 22 UK regional genetics laboratories. Hum Mutat 6:326-333.
43. Seibert FS, Linsdell P, Loo TW, Hanrahan JW, Clarke DM, Riordan JR. 1996a. Disease-associated mutations in the fourth cytoplasmic loop of CFTR compromise biosynthetic processing and chloride channel activity. J Biol Chem 271:15139-15143.
44. Seibert FS, Linsdell P, Loo TW, Hanrahan JW, Riordan JR, Clarke DM. 1996b. Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to regulation of chloride channel activity. J Biol Chem 271: 27493-27499.
45. Seibert FS, Loo TW, Clarke DM, Riordan JR. 1997. Cystic fibrosis: channel, catalytic, and folding properties of the CFTR protein. J Bioenerg Biomembr 29:429-442.
46. Sheppard DN, Welsh MJ. 1999. Structure and function of the CFTR chloride Channel. Physiological Reviews 79:323-S45.
47. Stern RC. 1997. The diagnosis of cystic fibrosis. N Engl J Med 336:487-491.
48. Teng H, Jorissen M, Van Poppel H, Legius E, Cassiman JJ, Cuppens H. 1997. Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. Hum Mol Genet 6:85-90.
49. ten Kate LP. 1990. Carrier screening for cystic fibrosis and other autosomal recessive diseases. Am J Hum Genet 47:359-361.
50. Tümmler B, Storrs T, Dziadek V, Dörk T, Meitinger T, Golla A, Bertele-Harms RM. 1996. Geographic distribution and origin of CFTR mutations in Germany. Hum Genet 97: 727-731.
51. Verlingue C, David A, Audrezet MP, Le Roux MG, Mercier B, Moisan JP, Ferec C. 1993. Asymptomatic carrier of two CFTR mutations: consequences for prenatal diagnosis? Pren Diagn 13:1143-1148.
52. Welsh MJ, Smith AE. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251-1254.
53. Zeitlin PL. 1999. Novel pharmacologic therapies for cystic fibrosis. J Clin Invest 103:447-452.
54. Zielenski J, Patrizio P, Corey M, Handelin B, Markiewicz D, Asch R, Tsui LC. 1995. CFTR gene variant for patients with congenital absence of vas deferens. Am J Hum Genet 57:958-960.